In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and ...

SECAUCUS, N.J., Feb. 2, 2026 /PRNewswire/ --Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the launch of a novel blood test that uses advanced ...

Quest Diagnostics Incorporated (NYSE:DGX) is one of the 7 most undervalued pot stocks to buy according to analysts. On June 10, the company said it is developing a Multi-Cancer Stratification (MCaST) ...

Please provide your email address to receive an email when new articles are posted on . Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for ...

Quest Diagnostics unveiled a first-to-market blood test available for consumer purchase that detects and measures the level of per- and polyfluorinated alkyl substances (PFAS), a potentially harmful ...

Quest Diagnostics (NYSE:DGX) is partnering with Guardant Health to offer Shield, an FDA-approved blood test for colorectal cancer screening, across its nationwide network. The agreement expands access ...

Years of exposure to nonstick cookware, fast-food packaging, fire-fighting gear and water-resistant household products have resulted in increased levels of PFAS, also known as "forever chemicals," in ...

(RTTNews) - Quest Diagnostics Incorporated (DGX), a provider of diagnostic information services, Tuesday said it partnered with The University of Texas MD Anderson Cancer Center to develop a ...

Quest Diagnostics may be the preferred lab your health insurance, doctors, or specialists use for blood work or other samples. We’re reviewing its sub-brand Quest Health, from which you can order your ...

Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Shield is the first and only blood test to receive full ...

Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J., July 9, ...